Development of Jin Medicine and Oncolytic Virus Platform Technology in Progress
Preclinical Completion Targeted by Year-End
Expanding Cancer Treatment Area Following ADC
Celltrion announced on the 27th that it has signed a joint research and development agreement for a systemically administered anticancer virus platform technology with Jin Medicine, a domestic anticancer virus developer.
Under this agreement, Celltrion will provide CT-P6 DS (active pharmaceutical ingredient) as the raw material for the systemically administered anticancer virus platform technology that uses 'Trastuzumab' as the targeting agent. Jin Medicine will be responsible for preclinical studies. Both companies plan to actively collaborate on the development of the platform technology by the end of this year, aiming to complete preclinical studies and exchange essential information required for preclinical trials.
Additionally, Celltrion has secured the right to exercise the global license priority negotiation rights for the platform technology after confirming the preclinical results.
Anticancer viruses are a technology that induces specific death of cancer cells using viruses and overexpresses cancer treatment genes in tumors, and they are being applied in the development of next-generation anticancer drugs. However, existing anticancer viruses are often rapidly eliminated when administered intravenously due to attacks by the human immune system. Low tumor specificity and low efficacy of systemic administration treatment have also been pointed out as limitations, prompting domestic and international companies to work on technological improvements.
Through collaboration with Celltrion, Jin Medicine has developed a proprietary technology for 'anticancer adenovirus' that coats the surface of the anticancer virus with an immunologically inert nanomaterial and binds to tumor-targeting sites, and has embarked on developing a systemically administered anticancer virus platform technology. In addition to developing this platform technology, Jin Medicine has developed four anticancer virus gene therapy pipelines and a local administration enhancement drug delivery system (DDS) platform technology. Furthermore, clinical development and commercialization of these are also underway.
A Celltrion official stated, "By participating in the development of this anticancer virus platform technology, we have expanded our anticancer domain beyond the anticancer antibody therapeutics already secured to include antibody-drug conjugates (ADC) under development, bispecific antibodies, and now the anticancer virus platform." He added, "We will continue to actively utilize collaborations with biotech companies possessing promising technologies and platforms like Jin Medicine to steadily pursue new drug development efforts."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
